Compare Quest Diagnostics Inc (DGX) vs Kimberly Clark Corp (KMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Kimberly Clark Corp — how do they compare? Quest Diagnostics Inc trades at $238.09 (market cap $26.21B), while Kimberly Clark Corp trades at $108.95 (market cap $36.11B). The key difference: Kimberly Clark Corp is the larger of the two by market cap, and Kimberly Clark Corp pays the higher dividend (4.72%). Which is the better fit depends on your goals.
| DGX | KMB | |
|---|---|---|
Market Cap | $26.21B | $36.11B |
Sector | Health | Consumer Staples |
52-Week High | $238.50 | $134.81 |
52-Week Low | $173.49 | $93.05 |
Enterprise Value | $31.97B | $41.67B |
Dividend Yield | 1.45% | 4.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.24, down 0.16% on the day, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $3.12 and raising its full-year outlook, driven by robust testing demand. Revenue grew to $11.04B in 2025, with net income of $992M, though margins face pressure from lower-margin deals and rising costs.
The outlook is positive due to raised guidance and AI integration enhancing efficiency, but risks include debt levels and margin compression. Analysts maintain a cautious buy stance with a $249.50 price target, indicating modest upside potential from current levels amid competitive and cost challenges.
Kimberly-Clark (KMB) trades at $109.47, up 1.34% today, with a neutral technical signal and bearish moving averages. Recent Q2 2026 earnings missed estimates due to China diaper disruptions and a distribution center fire, though gross margin expanded. The company maintains a strong dividend yield of 4.7% and an A credit rating. Analyst consensus is a $113.20 price target with 29% buy ratings, but near-term headwinds include softer consumer demand and inventory adjustments.
Outlook remains cautious with 2026 guidance trimmed; the stock offers value at a forward P/E of 14.6x and robust cash flow, but risks from China market volatility and input cost pressures persist. Institutional interest is mixed, with recent filings showing both new positions and trims. Long-term prospects hinge on innovation and productivity gains offsetting cyclical challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Kimberly Clark Corp
With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
Read more on KMB →
